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Summary 
With immunochemotherapy, remission duration and survival in patients with 
CLL is dependent on the level of minimal residual disease after treatment. This 
phase II trial assessed alemtuzumab consolidation post3chemotherapy in patients 
who responded with persistent low levels of detectable disease. Blood was screened 
for MRD using multi3parameter flow cytometry, 6 to 24 months post3chemotherapy. 
MRD3positive participants received alemtuzumab 30mg subcutaneously 3 times 
weekly for 6 weeks. Following a marrow assessment, MRD3negative participants or 
non3responders stopped therapy and MRD3positive participants with 1+ log reduction 
had 6 more weeks of alemtuzumab. Alemtuzumab consolidation was received by 47 
participants. One death and 19 of 22 serious adverse events reported from 17 (36%) 
participants were alemtuzumab related. MRD eradication from blood and bone 
marrow was achieved in 39 (83%) participants at the end of consolidation, with 18 
(38%) remaining MRD3negative in the blood 6 months later. Of the 18 MRD3negative 
participants at 6 months, the median time to MRD relapse was 46 months which was 
similar to patients who were MRD3negative at baseline and were followed up. The 53
year PFS and OS of MRD3negative participants at 6 months was significantly better 
than MRD3positive participants (PFS: 78%vs39% (p=0.010), OS: 89%vs64% 
(p=0.029)).  
Keywords: Chronic lymphocytic leukaemia, minimal residual disease, alemtuzumab  
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Introduction 
The treatment of Chronic Lymphocytic Leukaemia (CLL) has seen several advances 
over the past decade including advent of combination immunochemotherapy with 
Fludarabine, Cyclophosphamide and Rituximab (FCR) as the standard first line 
treatment and development of new agents such as several monoclonal antibodies, 
B3cell receptor signalling pathway inhibitors and BCL32 inhibitors. It is well 
established that with immunochemotherapy patients attaining complete 
remission (CR) have a better survival rate than those attaining partial response 
or less. This led to the concept of improving the depth of response up to the point of 
eradication of minimal residual disease (MRD), which is a standard practice in many 
other haematological malignancies	

. In CLL patients treated with 
different immunochemotherapy, Kwok et al has shown that attainment of MRD0
negativity is an independent predictor of Overall Survival (OS) and 
Progression0Free Survival (PFS) in a retrospective analysis(Kwok , 2009). In 
addition MRD3negativity following front3line FCR is a strong predictor of PFS and 
OS(Böttcher , 2012),(Strati , 2014). 
At the time of trial recruitment, alemtuzumab, a humanised monoclonal antibody 
specific for CD52, was licensed for the treatment of refractory CLL. But from 2012 
onwards alemtuzumab is available for this purpose only on patient access programs 
as it was withdrawn by the manufacturer due to non3medical reasons. However the 
trial still serves as a proof of principle for consolidation treatment, and there are 
several other effective monoclonal antibodies which can be used for further trials. 
Previous trials consistently showed that alemtuzumab is more efficacious when 
administered to patients with lower levels of disease, providing a rationale to use the 
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drug as consolidation when patients have only MRD detectable after 
chemoimmunotherapy and no bulk disease. The German CLL4B trial, a phase III trial 
to compare alemtuzumab consolidation against observation after purine analogue 
therapy, was prematurely stopped due to infection related toxicity(Wendtner , 
2004)
,
(Schweighofer , 2009). A long term follow up of the 21 participants has 
shown that PFS was significantly prolonged for the 11 treated participants vs. those 
in observation arm. Possible reasons for the toxicity were the proximity to initial 
therapy, the dose and the route of administration. In treatment for clinically 
progressive disease, the median duration of alemtuzumab therapy required to attain 
an MRD3negative CR was 9 weeks in a study of 91 participants(Moreton , 2005). 
The pharmacokinetics of alemtuzumab in MRD is more likely to be related to that 
observed in the bone marrow transplant setting than with conventional CLL 
treatment due to the low level of disease(Hale , 2004),(Rebello , 2001). Thus, 
for MRD level treatment, a reasonable dosing strategy was selected to be 30mg 
three times weekly subcutaneously for 6 weeks, at least 6 months after the last 
chemotherapy, with the treatment period extended to 12 weeks if necessary. 
Moreover careful surveillance for infection and pre3emptive treatment, if needed, 
would help to reduce the infection related toxicity in these patients.  
Methods 
Trial design 
CLL207 was a phase II, multi3centre, single3arm study, to determine the efficacy and 
safety of alemtuzumab consolidation in patients with low levels of MRD, definied as 
>1 CLL in 10,000 leucocytes, following conventional therapy. The joint primary 
endpoints were the MRD3negativity rate at the end of therapy and the proportion of 
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participants experiencing a predefined unacceptable level of toxicity. The secondary 
objectives were to assess clinical response to alemtuzumab therapy as defined by 
NCI Criteria, time to MRD relapse, progression free survival, overall survival and the 
pharmacokinetic profile of alemtuzumab in the MRD setting. An unacceptable toxicity 
was defined as any death or grade 3 or above toxicity attributed to the study 
treatment or its complications, excluding lymphopenia, grade 3 neutropenia or grade 
4 neutropenia responding to GCSF. A two stage design was planned to incorporate 
a stopping rule if the treatment was not felt to be acceptable in terms of either 
efficacy or toxicity. The sample size was determined using the Bryant and Day 
design which incorporates toxicity considerations as well as clinical responses(Bryant 
& Day, 1995). The calculation was based on the assumptions that an MRD rate over 
40% and toxicity rate under 20% is desired, and an MRD rate below 20% and toxicity 
rate above 40% is unacceptable. With 10% significance and 90% power, a total of 54 
participants were planned, with the stage I assessment after 24 participants. An 
independent Data Monitoring and Ethics Committee (DMEC) reviewed the safety 
and ethics of the study. The trial was approved by all relevant institutional ethical 
committees and regulatory review bodies, and was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice. 
Patients 
Eligible patients had completed chemotherapy for CLL between 6 to 24 months prior 
to registering, having attained a complete or partial remission. They did not have 
lymph nodes greater than 2cm in diameter by CT3scan nor a peripheral B3cell count 
more than 5 x 109/l, and had not received more than 3 prior therapies for CLL or an 
allogeneic transplant. Patients who previously failed alemtuzumab therapy and those 
with persisting severe pancytopenia due to previous therapy rather than disease 
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were also excluded. MRD status was assessed at entry; MRD3positive participants 
received consolidation therapy in the Main Study; MRD3negative participants were 
followed up within the study and only treated if they become MRD3positive during the 
eligibility period, otherwise they were followed under a Monitoring Investigation. 
Treatment 
Participants were treated with 30mg subcutaneous alemtuzumab three3times weekly 
for 6 weeks after which bone marrow and peripheral blood were assessed for MRD. 
Alemtuzumab was stopped if bone marrow was MRD3negative or if there was no 
significant improvement in the level of CLL cells. Participants who were responding 
but remained MRD3positive were treated with a further 6 weeks of alemtuzumab and 
then reassessed for MRD. Peripheral blood MRD status was reassessed every 3 
months after treatment. Participants were eligible to be retreated with alemtuzumab 
when they become MRD3positive, if they had remained MRD3negative for at least 6 
months (Figure 1). Standard antimicrobial prophylaxis for alemtuzumab were given 
including monitoring of CMV PCR. Participants with neutrophils below 1.0 x 109/l 
were treated with G3CSF (filgrastim 300Og three3times weekly on the days of 
alemtuzumab).  
Treatment was interrupted in the presence of the following events: platelets <25 x 
109/l or neutrophils<0.25 x 109/l, grade 4 non hematologic toxicity, and grades 3 to 4 
infection. Following the recovery of platelets to >50 x 109/l and neutrophils >0.5 x 
109/l, alemtuzumab was re3introduced. 
Response assessments 
MRD response assessments were based on the bone marrow MRD findings, and 
were categorised as follows: 
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	

No detectable CLL in the bone marrow and peripheral 
blood by 4 colour flow cytometry and  absence of lymphadenopathy and 
organomegaly attributed to CLL(Rawstron , 2007). 

: At least 1 logarithmic reduction in bone marrow CLL cells but still 
MRD3positive. 
: At least 1 logarithmic increase in bone marrow CLL cells or 
new clinically evident lymphadenopathy or splenomegaly. 
: Not falling into any of the above categories. 
Clinical response was also assessed according to the NCI response criteria 
1996(Cheson , 1996) 
Pharmacokinetics study 
A pharmacokinetics study was planned on consenting participants from selected 
centres. Serum alemtuzumab concentration was analysed using indirect 
immunofluorescence described by Rebello and Hale(Hale , 2004) at baseline,3, 6, 
9 and 12 weeks of treatment, where appropriate, and at 1, 2, 4, 6 and 12 weeks after 
treatment. 
Statistical methods 
Response rates derived based on bone marrow findings as well as NCI criteria are 
summarised for the Main Study population and 95% confidence intervals (CI) 
reported for the proportion of participants who became MRD3negative. Time to MRD 
relapse, PFS and OS are described using Kaplan3Meier curves. Safety is 
summarised by the number and proportion of participants who suffer an 
unacceptable toxicity, and 95% CIs reported. Details of the toxicities are also 
summarised using adverse event and treatment3related mortality rates. Planned 
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subgroup analyses summarise the primary endpoints, MRD relapse and survival 
data (where appropriate). 
Results 
Participant Characteristics 
Sixty3one participants with written informed consent were registered between 
December 2006 and January 2010 from 11 UK institutions with local ethical and 
management approval. 47 participants were treated within the Main Study, of which 
43 had detectable disease at registration and 4 became MRD3positive within 24 
months of completing their prior therapy. 11 participants remained in the Monitoring 
Investigation and 3 withdrew or were found to be ineligible before receiving 
treatment. The CONSORT diagram(Schulz , 2010)(Figure 2) shows the flow of 
participants throughout the trial. The recruitment target of 54 participants to the Main 
Study was not met due to slower than anticipated recruitment.  
Baseline characteristics of the participants in the Main Study are displayed in Table 
1. The median age was 58 years (range 40377) with 75% men. The relatively young 
population is expected given the concerns of additional toxicity with alemtuzumab. 
49% had received just one prior therapy, and 30% had received two (range 134). 
98% received prior fludarabine and 19% prior rituximab. 45% had responded to prior 
therapy with a CR and 55% with a PR. The mean neutrophil count of the participants 
was 2.91x109/l (range 0.735.1), lymphocyte count was 1.45x109/l (range 0.336.2), 
49% had a normal or high IgG level and 28% had a low but detectable IgG. 
Treatment 
The duration of treatment received is summarised in Table 2. Of the 47 
participants, 6(12.8%) did not receive the full 6 cycles as protocolled. 
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12(25.5%) participants were eligible to be treated for a further 6 weeks, and of 
these 4(33.3%) did not receive all 12 cycles. Reasons for early stopping included 
Adverse (AEs), CMV reactivation, cytopenia and participant choice. 20(42.6%) 
participants had a dose delay or modification for at least one week of treatment. 
Primary Endpoint Analysis 
At the analysis of stage I, reported to the DMEC in December 2008, 18/24(75.0%) 
participants responded to treatment with MRD3negativity, and 5(20.8%) suffered an 
unacceptable adverse reaction (AR), which did not pass the planned stopping 
boundaries. The DMEC felt that the toxicity was significant but manageable, and 
since the efficacy outcome was encouraging, the trial should proceed. 
At the stage II analysis, summarised in Table 2, 39/47 (83%; 95%CI: 69%392%) 
responded to treatment with MRD3negativity, which greatly exceeded the stopping 
boundary for efficacy of 13 responses. The denominator includes the participant with 
a missing response, to ensure the most conservative response rate by intention to 
treat. An unacceptable adverse reaction occurred in 10/47(21.3%), which was less 
than the stopping boundary of 15 participants, so the pre3defined stopping criteria 
were not met. 
Efficacy Endpoints 
The overall response rate (ORR), defined as complete or partial remission (CR/PR) 
by NCI Criteria, was 91.5% as summarised in Table 2. As of August 2015, the 
median follow0up for survivors was 6.3 years. The five0year PFS was 53.2%, 
and OS was 72.2%. Kaplan3Meier OS and PFS curves are presented in figures 3A 
and 3B respectively. The median time to progression was 70 months, and the 
median OS was not yet reached. 
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Of the 39 participants who became MRD0negative following treatment, the five0
year survival for MRD relapse, progression or death was 11.2%. The median 
duration of MRD3negativity was 6.7 months (95%CI: 5.6,25.0). 21/39 MRD3negative 
participants (53.8%) became MRD3positive within 6 months of completing therapy, 
and participants who remained MRD3negative beyond 6 months appeared to have a 
greater chance of sustained MRD3negativity, as illustrated by the Kaplan3Meier MRD 
curve presented in figure 3C. If MRD3negativity is assessed in the peripheral blood 6 
months after completing alemtuzumab, 18/47 participants (38%) reached this target 
(Table 2). PFS and OS was significantly better in the MRD3negative participants at 6 
months compared to those who were MRD3positive (p3values 0.010 and 0.029 
respectively) (figures 4A and 4B). 
Fifteen participants were MRD3negative at registration to the trial, 4 of whom became 
MRD3positive and were eligible for trial treatment, and the remaining 11 were 
followed up for relapse within the monitoring investigation. As of August 2015, the 
median follow3up from previous treatment in these 11 participants was 7 years, with 
one clinical progression at approximately 6 years after treatment and 2 deaths, both 
approximately 5 years after treatment. Ten of the 15 participants who were MRD3
negative at registration have relapsed to become MRD3positive or died. The median 
duration of MRD3negativity is 59.4 months (95%CI: 24.7,not reached), which was not 
significantly different to those patients who converted to MRD negativity when 
assessed 6 months after alemtuzumab consolidation, although the numbers for 
comparison are small (hazard ratio 1.57 (95%CI: 0.62,3.97)), figure 4C. 
Subgroup Analyses 
Nine participants went on to receive 11 or 12 weeks of therapy of which 6(67%) 
became MRD3negative by the end of treatment, but only 1(11%) remained MRD3
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negative at 6 months post3alemtuzumab. This suggests that there is no advantage to 
extend the therapy beyond 6 weeks.  
Nine participants had previously received rituximab; all became MRD3negative 
following therapy, and 2 (22%) remained MRD3negative after 6 months. None of 
these participants suffered an unacceptable toxicity. 
The MRD responses in participants who had received one (20/23(87%)) or multiple 
prior therapies (19/24(79%)) were comparable. After 6 months these response rates 
became 10/23(44%) and 8/24(33%) respectively. There was a trend towards more 
participants who had received multiple prior therapies suffering an 
unacceptable toxicity (7/24(29%) vs 3/23(13%)), and having a worse median 
PFS and OS (PFS 71 vs 45 months; OS not reached vs 60 months). Since the 
subgroup analyses are exploratory, it was not planned to assess significance 
in the differences between the subgroups, but the trends seen are expected 
due to the nature of the disease and treatment. 
Safety 
As of August 2015, 15 participants in the main trial (31.9%) have died. One death, 
caused by parainfluenza pneumonitis, was considered directly related to treatment. 
Two other deaths were the outcome of SAEs, although not directly related to 
treatment: myelodysplasia related infection and EBV driven lymphoproliferative 
disorder. Other causes of death were: 4 CLL related infections; 3 overwhelming 
tumour burden; 2 transformed disease; 1 Crohn's Disease; 1 pulmonary embolism; 1 
multiple myeloma. 22 SAEs were reported from 17(36.2%) participants, with 
19suspected to be related to alemtuzumab, of which 2 were unexpected (SUSARs): 
the parainfluenza infection resulting in death and an EBV related diffuse large B3cell 
lymphoma (DLBCL) leading to upper gastrointestinal haemorrhage. SAEs and AEs 
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are summarised in Table 2.Eleven events from 10 participants were considered 
unacceptable as per protocol definition. Four were considered highly unacceptable:1 
pneumocystis pneumonia;1 parainfluenza related death and 2 EBV related 
transformed diseases. Seven other events were easily manageable but considered 
unacceptable due to requirement of intravenous antibiotics (n=5), grade 4 
thrombocytopenia (n=1) and grade 4 neutropenia not responding to G3CSF (n=1).   
414 AEs were reported with 339 suspected to be alemtuzumab related, the most 
common being rashes(13%), cytopenia(13%), fatigue(8%), non3specific respiratory 
symptoms(8%) and fever(5%).Twenty3one(44.7%) of the treated participants had a 
positive CMV PCR during alemtuzumab;19(90.5%) occurred within the first 3 weeks 
of treatment. 30 participants received growth factor support, before treatment(n=3), 
while on treatment(n=12) or after treatment(n=15). The range of G3CSF support 
varied widely from pre3treatment to 27 months post treatment, with median 
duration11 months (range 0–67 months). 
Of the 12 participants receiving more than 6 weeks of treatment, 4 SAEs 
related to alemtuzumab were reported from 3 (25%) participants. Of these, only 
2 were reported after their 6th cycle. Of the 11 events that were deemed 
unacceptable, only 1 was from 1 participant who received 12 cycles (at cycle 
12). The other 10 were within the first 6 cycles. This may imply that most of the 
toxicity happens within the first 6 weeks of treatment itself. 
Pharmacokinetics study 
Serum alemtuzumab concentration was analysed in 5 participants. Lympholytic level 
was reached within 3 weeks (when the 1st post dose sample was tested) in all  
participants, unlike refractory patients treated with alemtuzumab in whom it took an 
average of 6 weeks to reach a concentration of 1Og/mL . The mean highest 
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concentration in individual participants was 8.24Og/mL(range2.70Og/mL3
11.97Og/mL), similar to the refractory patient group. The drug was detected in 
plasma up to 11 weeks after finishing treatment.  
Discussion 
Alemtuzumab consolidation is efficient, with 83% of participants attaining MRD3
negativity at the end of treatment. This high rate of MRD3negativity was not 
sustained, and 54% of MRD3negative participants relapsed at the MRD level in the 
peripheral blood by 6 months. At this time the MRD relapse curve flattened, 
suggesting that the 18 participants who remained MRD3negative in their peripheral 
blood at 6 months had a sustained MRD3negative response. Although a number of 
participants relapsed quickly at the MRD level, this did not translate into a fast 
clinical progression or death. Of the 47 treated participants, the 5 year PFS and OS 
rates were 53% and 72% respectively.  
Faster rate of MRD relapse within the first 6 months after treatment compared to 
beyond this period is probably explained by the redistribution of malignant cells 
between compartments. It is well described that alemtuzumab clears the disease in 
blood and marrow much more effectively than nodal disease. It seems likely that 
residual disease in lymph nodes redistributes to the blood and marrow within the first 
6 months after completing alemtuzumab suggesting that this is not a true relapse, 
but a redistribution of resistant disease. The participants who relapse beyond this 
initial 6 month period represent a true progression.  
This study also demonstrates that patients benefiting from alemtuzumab 
consolidation tend to respond within the first 6 weeks of treatment. In addition, 
peripheral blood MRD level at 6 months after consolidation is a truer indicator of 
persistent disease at MRD level than a marrow at the end of treatment, which would 
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be an unnecessary investigation as it is unlikely to change the future disease 
management.  
Participants who attained MRD3negativity have a better PFS and OS compared to 
those who remained MRD3positive. Previously, CALGB310101, an alemtuzumab 
consolidation trial, showed no statistically significant difference in 23years PFS and 
OS between consolidated and non3consolidated groups(PFS 76%68% p=0.35;OS 
84%88% p=1.0), but here the consolidation treatment was given only to 
participants in PR or SD, but not MRD3positive CRs(Lin , 2010). GermanCLL4B, 
however, randomised just 21 participants but showed a significant difference 
between participants who were consolidated vs not consolidated, with 33year PFS 
81.8% vs 30.0% (p=0.004)5, with participants receiving alemtuzumab having 
pronounced reductions in MRD levels. Long term follow up data from the German 
CLL8 trial has also shown that low (< 10−4) level MRD was associated with 
significantly better PFS and OS compared to intermediate (≥ 10−4 to <10−2) and 
high (≥ 10−2) level MRD(Böttcher , 2012). Although MRD negativity is not 
necessary to improve outcomes with certain therapies, such as B3cell receptor 
inhibitors, achieving MRD negativity is associated with a better outcome in all 
scenarios that have been studied and as one goal of future therapy is to move to a 
defined shorter duration of therapy MRD eradication will be an end3point that can be 
used to decide when to stop novel therapies such as ibrutinib or venetoclax. In this 
setting, as far as we know, the remission will be sustained only if the treatment 
is continued, but it will be useful to know whether a combination or 
consolidation with monoclonal antibodies will shorten the duration of therapy. 
This may have implication both in terms of toxicity of long term use as well as 
the cost of treatment. Alemtuzumab is not the right choice in this situation, 
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due to its toxic profile and non availability for commercial use, but this trial 
substantiates our understanding that attaining MRD negativity even with 
consolidation therapy can improve the survival outcome in CLL patients.  
Further analysis has shown that the MRD status at the end of treatment is not the 
accurate determinant of long3term PFS and OS (p=0.602 and p=0.780 respectively), 
but it is the MRD status 6 months after the treatment. The 53year PFS and OS of 
MRD3negative and positive participants at 6 months are 77.8% vs 39.3% (p=0.010) 
and 88.9% vs 63.9% (p=0.029) respectively. Their progression is similar to the 
participants who were MRD3negative at the entry of trial (HR=1.57 (95%CI: 
0.62,3.97)). Meaningful interpretations of subgroup analysis for various 
prognostic factors including genetic factors were not possible due to small 
numbers in each subgroup. 
Treatment is associated with substantial but manageable toxicity. Delaying the 
treatment to at least 6 months after the immediate prior treatment means that 
patients entering trial had a relative high proportion of normal haematological and 
other laboratory parameters. In addition, limiting the duration of treatment to 6 weeks 
reduces the chance of alemtuzumab being toxic to other CD52+ve targets like CD4+ 
T3cells. The pharmacokinetic study supports this shorter duration of treatment as the 
lympholytic dose is reached much earlier, as the disease burden is much smaller 
when compared to patients with clinical disease. Similarly patients who had more 
than one line of previous therapy experienced higher rate of unacceptable toxicity 
and had shorter PFS and OS. These suggest the need for careful patient selection 
and possibly consider consolidation at an earlier stage in the treatment line of CLL.  
In summary, the CLL207 trial is strongly suggestive that that consolidation of MRD3
positive to MRD3negative remissions after completing conventional chemotherapy 
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leads to a large improvement in outcome. However alemtuzumab in this setting 
carries a significant toxicity and it would be preferable to use a more specific 
monoclonal antibody that did not deplete T3cells. On the basis of the very promising 
sustained remissions seen in CLL207 we have commenced a randomised Phase III 
consolidation trial, the NCRI GALACTIC Trial, of the anti3CD20 antibody, 
obinutuzumab, which appears to result in MRD3negative remissions without the 
immune suppressive problems associated with alemtuzumab. 
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Figure Legends 
Figure 1: Study flow diagram 
Figure 2: CONSORT flow diagram 
Figure 3: (A) Progression3free survival and (B) overall survival of the treated 
population (C) MRD relapse in participants who were MRD3negative at end of 
therapy  
Figure 4: (A) Progression3free Survival and (B) overall survival by MRD status at 6 
months post treatment (C) survival outcomes for MRD relapse in participants who 
were MRD3negative at end of therapy compared to those who became MRD3
negative 6 months after consolidation
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Figure 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entered Main Study (n=47) 
♦Registered directly to main study (n=43) 
♦ Became eligible within monitoring 
investigation (n=4) 
Received treatment with alemtuzumab (n=47) 
 Does not meet eligibility criteria: 
♦Patient had clinically progressed (n=1) 
 
Registered with written informed consent (n=61) 
Did not enter MainStudy (n=14): 
♦ Not meeting inclusion criteria (n=2) 
♦ Declined to participate (n=1) 
♦ Registered to monitoring investigation 
without MRD relapse (n=11) 
 
Lost to follow3up (n=0) 
Discontinued intervention before 6 cycles (n=6) 
♦Adverse event (n=2) 
♦CMV reactivation (n=3) 
♦Patient issue (n=1) 
Discontinued intervention after 6 cycles (n=4) 
♦Adverse event (n=2) 
♦Patient issue (n=2) 
Analysed (n=47) 
Excluded from analysis (n=0) 
Pharmacokinetic analysis (n=5) 
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Table 1 Baseline Characteristics  
 
 
  Main Study 
(Treated 
Population) 
Monitoring Investigation 
(No Consolidation 
Treatment) 
Total 
Total 47 11 58 
Male 35 (74.5%) 8 (72.7%) 43 (74.1%) 
Age: median (range)  58.0 (40–77) 60.0 (44376) 58.5 (40377) 
Disease Stage (BINETS criteria) 
 Stage A 39 (83.0%) 5 (45.5%) 44 (75.9%) 
 Stage B 2 (4.3%) 2 (18.2%) 4 (6.9%) 
 Stage C 3 (6.4%) 0 (0.0%) 3 (5.2%) 
Number of Previous Lines of Therapy 
 1 23 (48.9%) 8 (72.7%) 31 (53.4%) 
 2 14 (29.8%) 3 (27.3%) 17 (29.3%) 
 334* 10 (21.3%) 0 (0.0%) 10 (17.2%) 
NCI Response to Previous Treatment 
 Complete Response 21 (44.7%) 8 (72.7%) 29 (50.0%) 
 Partial Response 26 (55.3%) 2 (18.2%) 28 (48.3%) 
Prior Fludarabine Treatment 46 (97.9%) 10 (90.9%) 56 (96.6%) 
Prior Rituximab Treatment 9 (19.1%) 2 (18.2%) 11 (19.0%) 
* The eligibility criteria were limited to 3 previous lines of therapy after two participants had 
already entered with 4.  
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Table 2 Treatment Duration, Efficacy and Safety Summaries 
 
 Main Study 
(Treated Population) 
Total 47 
Treatment Received 
 6 weeks 41(87.2%) 
 3 weeks  2 (4.3%) (1 AE (non3specific), 1 CMV 
reactivation) 
 4 weeks 3 (6.4%) (1 AE (Chronic Obstructive 
Pulmonary Disease); 2 CMV 
reactivation) 
 5 weeks 1 (2.1%) (participant choice) 
Eligible to continue beyond 6 weeks 12 (25.5%) 
 completed 12 weeks  8 (66.6%) 
 6 weeks 3 (25%) (1 cytopenia; 1 AE (non3
specific); 1 participant choice) 
 completed 11 weeks  1 (8.3%) (participant choice) 
MRD response following therapy (Efficacy Primary Endpoint) 
 MRD3Negative [95% CI] 39 (83.0%) [69.2%, 92.4%] 
 MRD3Positive 7 (14.9%) 
 Missing* 1 (2.1%) 
Unacceptable Treatment Related Toxicity (Safety Primary Endpoint) 
 Yes [95% CI] 10 (21.3%) [10.7%, 35.7%] 
 No 37 (78.7%) 
Overall Response 
 Achieved at least PR [95% CI] 43 (91.5%) [79.6%, 97.6%] 
  Complete Remission (CR)  27 (57.4%) 
  Partial Remission (PR)  7 (14.9%) 
  At least PR (Undeterminable CR)  9 (19.1%) 
 Did not achieve PR 3 (6.4%) 
  Stable Disease (SD)  3 (6.4%) 
  Progressive Disease (PD)  0 (0.0%) 
 Missing* 1 (2.1%) 
MRD response 6 months after treatment end 
 MRD3Negative 18 (38.3%) 
 MRDPositive 28 (59.6%) 
 Missing* 1 (2.1%) 
SAE Summaries 
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 Main Study 
(Treated Population) 
 Any participants with SAEs reported 17 (36.2%) 
  Total number of SAEs reported: 22 
   Suspected, unexpected 2 (9.1%) (1 parainfluenza related 
death, 1 EBV related DLBCL) 
   Suspected, expected 17 (77.3%) 
   Not suspected 3 (13.6%) 
 No SAEs reported 30 (63.8%) 
* The participant was too ill to have their sample taken. 
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